Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.
OBJECTIVE
Information available on HIV-2 and dual infection (HIV-1/2) is limited. This study was carried out among HIV positive individuals in an urban referral clinic in Khar, Mumbai, India, to report on relative proportions of HIV-1, HIV-2 and HIV-1/2 and baseline characteristics, response to and outcomes on antiretroviral treatment (ART).


METHODS
Retrospective analysis of programme data (May 2006-May 2009) at Khar HIV/AIDS clinic at Mumbai, India was done. Three test algorithm was used to diagnose HIV-1 and -2 infection. Standard ART was given to infected individuals. Information was collected on standardized forms.


RESULTS
A total of 524 individuals (male=51%; median age=37 yr) were included in the analysis over a 3 year period (2006-2009) - 489 (93%) with HIV-1, 28 (6%) with HIV-2 and 7(1%) with dual HIV-1/2 infection. HIV-2 individuals were significantly older than HIV-1 individuals (P<0.001). A significantly higher proportion of HIV-2 patients and those with dual infections had CD4 counts <200 cells/μl compared to HIV-1. HIV-2 individuals were more likely to present in WHO Clinical Stage 4. Of the 443 patients who were started on ART, 358 (81%) were still alive and on ART, 38 (8.5%) died and 3 were transferred out. CD4 count recovery at 6 and 12 months was satisfactory for HIV-1 and HIV-2 patients on protease inhibitor based regimens while this was significantly lower in HIV-2 individuals receiving 3 nucleoside reverse transcriptase inhibitors.


CONCLUSIONS
In an urban HIV clinic in Mumbai, India, HIV-2 and dual infections are not uncommon. Adaptation of the current national diagnostic and management protocols to include discriminatory testing for HIV types and providing access to appropriate and effective ART regimens will prevent the development of viral resistance and preserve future therapeutic options.
Medecins sans Frontieres, Mumbai, India.
Montaldo
M
Chiara
Zachariah
Z
Rony
Mansoor
M
Homa
Varghese
V
Bhanumati
Joanna
J
Ladomirska
M
M
Manzi
N
N
Wilson
Deshpande
D
Alaka
A D
AD
Harries
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002947:Cities; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology*; D015497:HIV-1; D015498:HIV-2; D006801:Humans; D007118:Immunoassay; D007194:India / Q000453:epidemiology; D008297:Male; D015995:Prevalence; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
J Clin Microbiol. 2004 Sep;42(9):4147-53
15365003
Science. 1994 Sep 9;265(5178):1587-90
7915856
AIDS. 2004 Apr 9;18(6):887-95
15060436
Lancet. 2002 Jul 6;360(9326):34-40
12114039
J Antimicrob Chemother. 2006 Apr;57(4):709-13
16464891
JAMA. 2006 Aug 16;296(7):782-93
16905784
AIDS. 2008 Apr 23;22(7):873-82
18427206
AIDS. 1994 Nov;8(11):1617-20
7848600
Antivir Chem Chemother. 1999 Jul;10(4):211-7
10480739
J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):336-43
16249709
AIDS. 2006 Feb 14;20(3):459-62
16439883
J Med Dent Sci. 1999 Mar;46(1):53-62
12160214
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 15;16(5):327-32
9420309
Lancet. 1992 Aug 8;340(8815):339-40
1353807
Transfusion. 1988 Mar-Apr;28(2):192-5
3354049
J Infect. 2001 Feb;42(2):126-33
11531319
AIDS. 2003 Jul;17 Suppl 3:S49-54
14565609
Lancet. 1994 Apr 16;343(8903):943-6
7909009
Indian J Med Res. 1992 Sep;95:213-5
1478722
Lancet. 1990 May 5;335(8697):1103-4
1970407
AIDS. 2002 Sep 6;16(13):1775-83
12218389
AIDS. 1996 Jun;10(7):689-99
8805859
AIDS. 1993 Jul;7(7):989-93
8357558
Antivir Ther. 2004 Feb;9(1):3-12
15040531
BMJ. 1994 Feb 12;308(6926):441-3
8124173
Ghana Med J. 2008 Mar;42(1):16-21
18560550
Zentralbl Bakteriol. 1994 Jan;280(3):398-402
8167434
JAMA. 1994 Aug 10;272(6):462-6
8040982
Indian J Med Res. 1993 Mar;97:49-52
8505073